Genentech & Why Patient Engagement Is So Important Right Now
As expectations rise across regulatory, commercial, and advocacy landscapes, teams are under growing pressure to demonstrate the real impact of their patient engagement efforts. At this year’s Measuring Patient Engagement Summit, Genentech will share a practical, outcomes‑focused approach to measuring the value of partnerships with patient advocacy organizations - moving beyond activity reporting to true impact assessment.
In this interview, we explore how Genentech evaluates engagement across operations, R&D, market access, and corporate reputation, as well as the frameworks they use to capture outcomes that matter to both internal teams and patient communities. From health‑equity collaborations to endpoint optimization, this conversation highlights why patient engagement has shifted from a “nice‑to‑have” to an essential evidence requirement - and how teams can build measurement systems that reflect that shift.
What Specific Metrics, KPIs, or Measurement Approaches Will You Be Sharing in Your Session?
Measuring performance and impact of corporate memberships with patient advocacy organizations. Metrics can include:
- Operations (e.g., retention rate, engagement type and frequency, functions, relationships, compliance, etc.)
- R&D (e.g., protocol optimization, recruitment acceleration, patient-centered endpoints, diversity, and representation, etc.)
- Market access and policy (e.g., patient-payer submissions, policy initiatives, etc.)
- Corporate reputation (e.g., Patient View report, net promoter score, voice of patient integration, etc.)
Additionally, a framework that helps to measure the impact of patient engagement for both internal industry team members and patient advocates and organizations.
What Concrete Tools, Frameworks, or Outputs Will Attendees Walk Away With?
Attendees will leave and know how to structure corporate memberships with patient advocacy organizations and how to measure the impact of patient engagement on both internal teams and external patient organizations.
Can You Share One Example of How These Metrics Influenced a Real Decision?
Yes. One example: Genentech’s partnership with ACS on health equity and clinical navigation (“Get screened”) beyond just reporting “dollars donated.”
- More than 1.4M additional people screened for cancer
- More than 18,000 cancers diagnosed since 2020
What’s One Common Mistake Teams Make When Trying to Measure Patient Engagement?
Mistaking “activity” with “impact” - reporting on output rather than on outcomes.
Example: The mistake (activity): “We held 4 advisory board meetings this year”
The goal (impact): “We changed 1 primary and 1 secondary endpoints in Phase III protocol based on advisory board feedback.”
Why Is This Topic Particularly Important for Teams Right Now?
Patient engagement has shifted from a nice-to-have corporate social responsibility to a core evidence requirement for regulatory and commercial teams (e.g., PFDD roadmap, IRA/CMS evidence package, EU JCA). Today, patient input is not only a data point in regulatory filings but also a value driver for access.
What Are You Most Looking Forward to at the Summit?
Learning from my peers on how they measure patient engagement, sharing best practices, and co-creating effective KPI frameworks.
Don’t Miss Out
Learn more about the summit this May by accessing the event brochure here. Additionally, tickets are currently available so if your team are looking to attend this year’s meeting, don’t delay and register today.